Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
04 Gennaio 2024 - 1:59PM
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company
decoding biology to industrialize drug discovery, today announced
it has signed an agreement with Bayer AG to in-license a new
chemical entity that emerged from the companies’ fibrosis research
collaboration. The compound represents a novel approach to treating
fibrotic diseases with compelling early data suggesting the
potential to reverse disease-related fibrotic processes, including
immuno-mesenchymal dysfunction.
“Since initiating our research collaboration with Bayer in 2020,
we have worked diligently to apply the power of the Recursion OS to
identify and advance potential candidates in challenging areas of
disease biology,” said Chris Gibson, Ph.D., Co-founder and CEO of
Recursion. “We are excited to bring this asset into our internal
pipeline and accelerate the compelling science behind this program
while our research collaboration with Bayer focuses on precision
oncology.”
Recursion applied phenotypic screening of human cells to
identify small molecules that reverse the phenotypic features of
disease-state fibrocyte cells into those of healthy-state cells.
Leveraging the power of Recursion’s Maps of Biology and Chemistry
revealed a relationship between small molecule hits and a novel
target that could impact fibrotic diseases. The most promising
small molecule hits were confirmed as potent inhibitors of this
novel target in validation experiments, and lead optimization
studies are currently ongoing.
Fibrotic diseases are a significant cause of morbidity and
mortality worldwide with high unmet need for patients. One of the
biggest challenges in the treatment of fibrotic diseases is the
underlying complex biology and the associated difficulty in
discovering disease-modifying drug targets. Recursion’s technology
is uniquely suited to accelerate discoveries in these and other
complex areas of disease biology.
About RecursionRecursion (NASDAQ: RXRX) is a
clinical stage TechBio company leading the space by decoding
biology to industrialize drug discovery. Enabling its mission is
the Recursion OS, a platform built across diverse technologies that
continuously expands one of the world’s largest proprietary
biological and chemical datasets. Recursion leverages sophisticated
machine-learning algorithms to distill from its dataset a
collection of trillions of searchable relationships across biology
and chemistry unconstrained by human bias. By commanding massive
experimental scale — up to millions of wet lab experiments weekly —
and massive computational scale — owning and operating one of the
most powerful supercomputers in the world, Recursion is uniting
technology, biology, and chemistry to advance the future of
medicine.
Recursion is headquartered in Salt Lake City, where it is a
founding member of BioHive, the Utah life sciences industry
collective. Recursion also has offices in Toronto, Montréal and the
San Francisco Bay Area. Learn more at www.Recursion.com, or connect
on Twitter and LinkedIn.
Media ContactMedia@Recursion.com
Investor
ContactInvestor@Recursion.com
Forward-Looking StatementsThis document
contains information that includes or is based upon
"forward-looking statements" within the meaning of the Securities
Litigation Reform Act of 1995, including, without limitation, those
regarding early and late stage discovery, preclinical, and clinical
programs; licenses and collaborations; prospective products and
their potential future indications and market opportunities;
Recursion OS and other technologies; business and financial plans
and performance; and all other statements that are not historical
facts. Forward-looking statements may or may not include
identifying words such as “plan,” “will,” “expect,” “anticipate,”
“intend,” “believe,” “potential,” “continue,” and similar terms.
These statements are subject to known or unknown risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied in such statements, including but
not limited to: challenges inherent in pharmaceutical research and
development, including the timing and results of preclinical and
clinical programs, where the risk of failure is high and failure
can occur at any stage prior to or after regulatory approval due to
lack of sufficient efficacy, safety considerations, or other
factors; our ability to leverage and enhance our drug discovery
platform; our ability to obtain financing for development
activities and other corporate purposes; the success of our
collaboration activities; our ability to obtain regulatory approval
of, and ultimately commercialize, drug candidates; our ability to
obtain, maintain, and enforce intellectual property protections;
cyberattacks or other disruptions to our technology systems; our
ability to attract, motivate, and retain key employees and manage
our growth; inflation and other macroeconomic issues; and other
risks and uncertainties such as those described under the heading
“Risk Factors” in our filings with the U.S. Securities and Exchange
Commission, including our Annual Report on Form 10-K. All
forward-looking statements are based on management’s current
estimates, projections, and assumptions, and Recursion undertakes
no obligation to correct or update any such statements, whether as
a result of new information, future developments, or otherwise,
except to the extent required by applicable law.
Grafico Azioni Recursion Pharmaceuticals (NASDAQ:RXRX)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Recursion Pharmaceuticals (NASDAQ:RXRX)
Storico
Da Set 2023 a Set 2024